Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

This study is testing a radioactive treatment called PRRT (peptide receptor radionuclide therapy), which targets specific receptors on tumor cells, before surgery in people with metastatic neuroendocrine tumors (NETs) of the digestive system or pancreas. Researchers want to see if PRRT before surgery leads to better outcomes. **You may be eligible if...** - You have metastatic neuroendocrine tumors in the gut or pancreas (gastroenteropancreatic NET) with spread to lymph nodes or liver only - Your tumor is low to intermediate grade (WHO Grade 1 or 2, Ki-67 ≤ 20%) - A tumor board has determined your cancer can be surgically removed - Your tumors show up on a specific type of scan (68Ga DOTA TATE PET) - You are 18 or older and in reasonably good health **You may NOT be eligible if...** - Your cancer has spread beyond lymph nodes and liver - You have significant kidney, liver, or blood count problems - You are pregnant or breastfeeding - You have had prior PRRT treatment Talk to your doctor to see if this trial is right for you.